124 related articles for article (PubMed ID: 1640710)
21. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
22. Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer.
Papadimitriou CA; Dimopoulos MA; Ampela C; Louvrou-Fertaki A; Anagnostopoulos A; Athanassiades P; Stamatelopoulos S; Keramopoulos A
Oncology; 1998; 55(6):533-7. PubMed ID: 9778619
[TBL] [Abstract][Full Text] [Related]
23. Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study.
Saphner T; Tormey DC; Albertini M
Cancer; 1991 Dec; 68(11):2359-62. PubMed ID: 1933771
[TBL] [Abstract][Full Text] [Related]
24. Treatment of advanced non-small cell lung cancer (NSCLC): the "Umbria" cooperative study.
Crinó L; Darwish S; Corgna E; Meacci ML; Di Costanzo F; Buzzi F; Fornari G; Santi F; Ballatori E; Luccioli L
Semin Oncol; 1988 Dec; 15(6 Suppl 7):52-5. PubMed ID: 2851180
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin and etoposide in chemotherapy-refractory advanced breast cancer.
Giaccone G; Donadio M; Ferrati P; Calciati A
Tumori; 1988 Apr; 74(2):191-3. PubMed ID: 3368973
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
[TBL] [Abstract][Full Text] [Related]
27. VP-16 and adriamycin in patients with advanced breast cancer.
Vaughn CB; Maniscalco-Greb E; Lockhard C; Groshko G; Enochs K; Duffin H; Demitrish M
Am J Clin Oncol; 1982 Oct; 5(5):505-9. PubMed ID: 6897491
[TBL] [Abstract][Full Text] [Related]
28. Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy.
Athanassiades P; Bacoyiannes H; Kontoyiannes D
Chemioterapia; 1986 Apr; 5(2):125-7. PubMed ID: 3518965
[TBL] [Abstract][Full Text] [Related]
29. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Kasseyet S; Astoul P; Boutin C
Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
[TBL] [Abstract][Full Text] [Related]
31. The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer.
Kojima T; Hoshino A; Ohara K; Kamiya O; Nagata K; Ito Y; Kinoshita T; Sugiura I; Yamada M; Sato H
Cancer Chemother Pharmacol; 1985; 15(3):268-71. PubMed ID: 3902267
[TBL] [Abstract][Full Text] [Related]
32. Adriamycin (doxorubicin), vinblastine, and mitomycin C combination chemotherapy in refractory breast carcinoma.
Luikart SD; Witman GB; Portlock CS
Cancer; 1984 Oct; 54(7):1252-5. PubMed ID: 6467151
[TBL] [Abstract][Full Text] [Related]
33. Ifosfamide, methotrexate, and 5-fluorouracil in advanced pretreated breast cancer.
Becher R; Höfeler H; Kloke O; Kurschel E; Schilcher RB; Weinhardt O; Wandl U; Schmidt CG
Semin Oncol; 1989 Feb; 16(1 Suppl 3):56-9. PubMed ID: 2495568
[TBL] [Abstract][Full Text] [Related]
34. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
35. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy.
Blumenschein GR; DiStefano A; Caderao J; Fristenberg B; Adams J; Schweichler LH; Drinkard L
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2633-7. PubMed ID: 10068266
[TBL] [Abstract][Full Text] [Related]
36. Cyclophosphamide, epirubicin and cisplatin (CEP) in advanced breast cancer: preliminary results.
Zaniboni A; Marpicati P; Simoncini E; Gorni F; Ferrari V; Raffaglio E; Garattini MP; Marini G
Anticancer Res; 1987; 7(4B):813-5. PubMed ID: 3479042
[TBL] [Abstract][Full Text] [Related]
37. [CMF or CAF combination chemotherapy for breast cancer].
Ota J
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1886-90. PubMed ID: 8978791
[TBL] [Abstract][Full Text] [Related]
38. Etoposide (VP-16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
J Surg Oncol; 1986 May; 32(1):43-5. PubMed ID: 3724190
[TBL] [Abstract][Full Text] [Related]
39. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
[TBL] [Abstract][Full Text] [Related]
40. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
